Obtained the drug registration certificate for Quetiapine Fumarate Sustained-Release Tablets
June 17, 2025
Source: drugdu
44
June 15, Huahai Pharmaceutical(600521.SH) announced that the company recently received the "Drug Registration Certificate" for Quetiapine Fumarate Sustained-Release Tablets approved and issued by the State Drug Administration. The drug is used to treat depressive episodes of schizophrenia and bipolar disorder. It was first developed by AstraZeneca and launched in the United States in 2007. According to the data of Minnet, the domestic market sales amount in 2024 will be about 451 million yuan. Huahai Pharmaceutical has invested about 16.93 million yuan in research and development expenses in this project. The approval of this drug further enriches the company's product line, enhances market competitiveness, and has a positive effect on business development.
https://finance.eastmoney.com/a/202506153430842883.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer July 7, 2025
- Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety July 7, 2025
- Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year July 7, 2025
- LH-1801 project enters Phase III clinical trial July 7, 2025
- The new generation of DNA biosynthesis technology is moving towards industrialization July 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
